<DOC>
	<DOCNO>NCT02668562</DOCNO>
	<brief_summary>Ticagrelor , potent P2Y12 inhibitor , show reduce major adverse cardiac event ( MACE ) acute coronary syndrome ( ACS ) . It increasingly use first line therapy ACS . However , potent P2Y12 inhibition associate increase bleeding . This may particular concern patient ACS require coronary artery bypass surgery ( CABG ) . In particular , time cessation ticagrelor proceed CABG unclear . RAPID TITRATE CABG randomize vanguard study evaluate feasibility preliminary safety strategy early versus delay CABG ACS patient initially treat ticagrelor identify potential mechanism underlie benefit complication early bypass surgery .</brief_summary>
	<brief_title>Timing Coronary Artery Bypass Surgery Among Patients With Acute Coronary Syndromes Initially Ticagrelor</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>ACS patient refer CABG receive &gt; = 1 dose ticagrelor decision CABG make Patients excluded : refuse consent enrollment deem require immediate CABG ( Day 0 day 1 ) STelevation myocardial infarction ( STEMI ) initially treat primary PCI undergo concurrent valve surgery intolerant allergic aspirin oral anticoagulant ( include vitamin K antagonist NOAC ) receive adjuvant therapy glycoprotein IIbIIIa inhibitor comorbidity lifeexpectancy &lt; 1 year active bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>acute coronary syndrome</keyword>
	<keyword>coronary artery bypass surgery</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>antiplatelet therapy</keyword>
	<keyword>platelet function test</keyword>
</DOC>